Integumen said initial aggregate low six-figure payments have already been received.
Under the framework agreements being rolled out, research and development teams in the US, Asia and the EU will collaborate with the LabskinAI virtual lab to test existing products and work on new product development on LabskinAI.
The collaborators will make full use of Integumen’s healthy and diseased living skin models.
"We are still only at the beginning with LabskinAI and privileged to be working with these leading household names so quickly,” said Gerard Brandon, the chief executive officer of Integumen.
“These are data-driven engagements and recognise that non-animal testing on Labskin human skin equivalents combined with AI [artificial intelligence] deep analytics is the way forward for the skincare industry. Clients can now assess how formulations are reacting on top of and deep into the skin microbiome, which will create better, safer, more cost-effective products that meet increasing compliance requirements,” he added.
"With the promise of potential contract extensions in the future with existing clients and new contracts in the pipeline, we are excited that our new laboratories in York will soon be coming on stream to meet this growing demand. Even with only two months of the new additional lab space, management are confident that group revenue will exceed £1mln by our year-end,” Brandon revealed.
Virtual diseased skin
In a separate announcement, Integumen revealed the LabskinAI teams have completed an artificially intelligent virtual psoriasis skin model.
Following genomic sequencing of samples taken from 671 patients, the resulting datasets identified 216 species of microbiota (bacteria, virus and fungi) that were subsequently confirmed using several different AI algorithms.
Following the testing of various types, a reliable psoriasis model was identified and was confirmed through a cross-validation process. In total, 33 species were identified that are critical to the success of the Labskin AI diseased skin model for analysing psoriasis.
The continued addition of patient data will further increase the accuracy of the psoriasis model. This AI dataset model can also be used to develop other diseased skin models such as atopic dermatitis, rosacea and acne.
"Integumen is at the forefront of AI development for the skin care industry,” Brandon declared.
“AI diseased skin models are the new frontier and are a disruptive platform for new drug discovery. This has the ability to transform the research and development of diseased skin treatments, making them a lot less expensive and bring products to the market faster. This is why large skin care companies are signing up to use LabskinAI, as reported in the RNS [regulated news service story] issued earlier today," the Integumen chief executive said.